GSK's Novel ADC Shows Strong Phase 1 Efficacy in Gynaecological Cancers, Advances to Five Pivotal Phase 3 Trials
GSK sits 79% above its 52-week low of $32.38.
Summary
GSK announced positive Phase 1 clinical trial results for mocertatug rezetecan (Mo-Rez), a novel antibody-drug conjugate, demonstrating high objective response rates in platinum-resistant ovarian and endometrial cancers, leading to the initiation of five pivotal Phase 3 trials.
Key Events · Product Development and Regulatory · GSK
-
Positive Phase 1 Results
Mocertatug rezetecan (Mo-Rez), a novel B7-H4-targeted antibody-drug conjugate, achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer in the BEHOLD-1 study.
-
Advancement to Phase 3
Based on these promising efficacy and safety findings, GSK will initiate five pivotal global Phase 3 trials for Mo-Rez in 2026 across various gynaecological cancer settings, including earlier-line treatments.
-
Addresses Unmet Need
The observed responses are higher than typically seen in ADCs in development for these gynaecological cancers, where current treatment options are limited, reinforcing Mo-Rez's broad potential.
Analysis · GSK · Life Sciences
This filing highlights a significant advancement in GSK's oncology pipeline with a novel antibody-drug conjugate, Mo-Rez. The strong objective response rates observed in Phase 1 for difficult-to-treat gynaecological cancers, coupled with a manageable safety profile, provide compelling evidence for its potential. The decision to rapidly move into five pivotal Phase 3 trials underscores the company's confidence in Mo-Rez as a future growth driver and addresses a substantial unmet medical need. Investors should monitor the progress of these upcoming Phase 3 trials as they will be critical for the drug's eventual market approval and commercial success.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $58.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $117B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.